Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX – Get Free Report) saw unusually-strong trading volume on Monday. 231,111 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 221,552 shares. The stock last traded at $11.5550 and had previously closed at $11.45.
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Friday. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, September 23rd. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Telix Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $20.50.
Read Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Stock Up 1.3%
Institutional Investors Weigh In On Telix Pharmaceuticals
Large investors have recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth $1,731,000. Private Advisor Group LLC grew its stake in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the last quarter. XY Capital Ltd increased its stake in shares of Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after acquiring an additional 58,739 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. Finally, Lazard Asset Management LLC raised its position in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter.
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.
The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.
Featured Articles
- Five stocks we like better than Telix Pharmaceuticals
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
- 2 China-Focused ETFs For After the Trump-Xi Summit
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
